Glioblastoma: Pathogenesis and Current Status of Chemotherapy and Other Novel Treatments

Role of Notch Signaling Pathway in Glioblastoma Multiforme Pathogenesis

(2019) Riccardo Bazzoni et al.   Cancers

Virus-Based Immunotherapy of Glioblastoma

(2019) Miika Martikainen et al.   Cancers

Phase I trial of alisertib with concurrent fractionated stereotactic re-irradiation for recurrent high grade gliomas

(2019) Andrew Song et al.   RADIOTHERAPY AND ONCOLOGY

Consequences of IDH1/2 Mutations in Gliomas and an Assessment of Inhibitors Targeting Mutated IDH Proteins

(2019) Bozena Kaminska et al.   MOLECULES

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial

(2019) Ulrich Herrlinger et al.   LANCET

A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma

(2019) Jiayi Huang et al.   JOURNAL OF NEURO-ONCOLOGY

Multicenter, single arm, phase II trial on the efficacy of ortataxel in recurrent glioblastoma

(2019) Antonio Silvani et al.   JOURNAL OF NEURO-ONCOLOGY

Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial

(2019) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Current State of Immunotherapy for Treatment of Glioblastoma

(2019) Tresa McGranahan et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

A Characterization of Dendritic Cells and Their Role in Immunotherapy in Glioblastoma: From Preclinical Studies to Clinical Trials

(2019) Siddhartha Srivastava et al.   Cancers

Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma

(2019) Thomas J. Kaley et al.   JOURNAL OF NEURO-ONCOLOGY

Phase II study of Dovitinib in recurrent glioblastoma

(2019) Mayur Sharma et al.   JOURNAL OF NEURO-ONCOLOGY

Isocitrate Dehydrogenase Mutations in Glioma: From Basic Discovery to Therapeutics Development

(2019) Juan Huang et al.   Frontiers in Oncology

Macrophage Exclusion after Radiation Therapy (MERT): A First in Human Phase I/II Trial using a CXCR4 Inhibitor in Glioblastoma

(2019) Reena P Thomas et al.   CLINICAL CANCER RESEARCH

First-in-Human Phase I Clinical Trial of Pharmacologic Ascorbate Combined with Radiation and Temozolomide for Newly Diagnosed Glioblastoma

(2019) Bryan G. Allen et al.   CLINICAL CANCER RESEARCH

Open-Label Phase II Evaluation of Imatinib in Primary Inoperable or Incompletely Resected and Recurrent Glioblastoma

(2019) Lisa Sautter et al.   ONCOLOGY

Phase II trial of ponatinib in patients with bevacizumab‐refractory glioblastoma

(2019) Eudocia Q. Lee et al.   Cancer Medicine

A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study

(2019) Sarah Lapointe et al.   INVESTIGATIONAL NEW DRUGS

Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II)

(2019) John D. Hainsworth et al.   JOURNAL OF NEURO-ONCOLOGY

Health-related quality of life and neurocognitive functioning with lomustine–temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial

(2019) Johannes Weller et al.   LANCET ONCOLOGY

INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFRamplified glioblastoma

(2019) Martin van den Bent et al.   NEURO-ONCOLOGY

A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)

(2019) Timothy F Cloughesy et al.   NEURO-ONCOLOGY

Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial

(2018) H -G Wirsching et al.   ANNALS OF ONCOLOGY

Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572

(2018) David Schiff et al.   CANCER

A highlight on Sonic hedgehog pathway

(2018) Gabriela Basile Carballo et al.   Cell Communication and Signaling

Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients

(2018) Nader Sanai et al.   CLINICAL CANCER RESEARCH

Magnetic hyperthermia therapy for the treatment of glioblastoma: a review of the therapy’s history, efficacy and application in humans

(2018) Keon Mahmoudi et al.   INTERNATIONAL JOURNAL OF HYPERTHERMIA

Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment

(2018) Xiao-Tang Kong et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas

(2018) Antonio Omuro et al.   JOURNAL OF CLINICAL ONCOLOGY

Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma

(2018) Jiayi Huang et al.   JOURNAL OF NEURO-ONCOLOGY

JCOG0911 INTEGRA study: a randomized screening phase II trial of interferonβ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma

(2018) Toshihiko Wakabayashi et al.   JOURNAL OF NEURO-ONCOLOGY

Tumor treating fields: a new approach to glioblastoma therapy

(2018) Jonathan Rick et al.   JOURNAL OF NEURO-ONCOLOGY

High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients

(2018) Alfredo Marinelli et al.   MEDICINE

Current state of immunotherapy for glioblastoma

(2018) Michael Lim et al.   Nature Reviews Clinical Oncology

CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges

(2018) Stephen J Bagley et al.   NEURO-ONCOLOGY

OUP accepted manuscript

(2018)   NEURO-ONCOLOGY

OUP accepted manuscript

(2018)   NEUROSURGERY

Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG)

(2018) Germán Reyes‐Botero et al.   ONCOLOGIST

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers

(2018) Janeta Popovici-Muller et al.   ACS Medicinal Chemistry Letters

Anti-Angiogenics: Current Situation and Future Perspectives

(2018) Katja Zirlik et al.   Oncology Research and Treatment

Advances in Radiotherapy for Glioblastoma

(2018) Justin Mann et al.   Frontiers in Neurology

Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma

(2018) Martin J. B. Taphoorn et al.   JAMA Oncology

Molecular Targeting of Acid Ceramidase in Glioblastoma: A Review of Its Role, Potential Treatment, and Challenges

(2018) Ha Nguyen et al.   Pharmaceutics

Role of mTOR Signaling in Tumor Microenvironment: An Overview

(2018) Fabiana Conciatori et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Molecular mechanism of Notch signaling with special emphasis on microRNAs: Implications for glioma

(2018) Du Yan et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma

(2018) Jennie W. Taylor et al.   JOURNAL OF NEURO-ONCOLOGY

Inhibition of sonic hedgehog and PI3K/Akt/mTOR pathways cooperate in suppressing survival, self-renewal and tumorigenic potential of glioblastoma-initiating cells

(2018) Rajesh Nanta et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011–2015

(2018) Quinn T Ostrom et al.   NEURO-ONCOLOGY

A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma

(2018) Alba A. Brandes et al.   ONCOLOGIST

PDGF-mediated mesenchymal transformation renders endothelial resistance to anti-VEGF treatment in glioblastoma

(2018) Tianrun Liu et al.   Nature Communications

Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma

(2018) Stefania Maraka et al.   CANCER

Targeting mTOR in Glioblastoma: Rationale and Preclinical/Clinical Evidence

(2018) Carmen Mecca et al.   DISEASE MARKERS

Phase 2 Study of Radiation Therapy Plus Low Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420

(2018) Frank S. Lieberman et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial

(2018) Giuseppe Lombardi et al.   LANCET ONCOLOGY

Intracerebral injection of CpG oligonucleotide for patients with de novo glioblastoma—A phase II multicentric, randomised study

(2017) Renata Ursu et al.   EUROPEAN JOURNAL OF CANCER

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma

(2017) Roger Stupp et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine–DNA Methyltransferase Biomarker Analyses

(2017) Timothy Cloughesy et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas

(2017) Katherine B. Peters et al.   JOURNAL OF NEURO-ONCOLOGY

Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02

(2017) Phioanh Leia Nghiemphu et al.   JOURNAL OF NEURO-ONCOLOGY

Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma

(2017) J. Duerinck et al.   JOURNAL OF NEURO-ONCOLOGY

Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study

(2017) Andrew Yu et al.   JOURNAL OF NEURO-ONCOLOGY

Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas

(2017) Lakshmi Nayak et al.   JOURNAL OF NEURO-ONCOLOGY

The role of radiation in treating glioblastoma: here to stay

(2017) Christopher D. Corso et al.   JOURNAL OF NEURO-ONCOLOGY

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

(2017) Michael Weller et al.   LANCET ONCOLOGY

Tumour heterogeneity and resistance to cancer therapies

(2017) Ibiayi Dagogo-Jack et al.   Nature Reviews Clinical Oncology

Phase II trial of dacomitinib, a pan–human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification

(2017) Juan Manuel Sepúlveda-Sánchez et al.   NEURO-ONCOLOGY

Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy

(2017) Timothy F Cloughesy et al.   NEURO-ONCOLOGY

Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02

(2017) Evanthia Galanis et al.   NEURO-ONCOLOGY

Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy

(2017) Patrick Y Wen et al.   NEURO-ONCOLOGY

A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913

(2017) Prakash Chinnaiyan et al.   NEURO-ONCOLOGY

Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143

(2017) Antonio Omuro et al.   NEURO-ONCOLOGY

Phase I/II Study of Temozolomide Plus Nimustine Chemotherapy for Recurrent Malignant Gliomas: Kyoto Neuro-oncology Group

(2017) Tomokazu AOKI et al.   NEUROLOGIA MEDICO-CHIRURGICA

Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma

(2017) Ashley Ghiaseddin et al.   ONCOLOGIST

Acid ceramidase confers radioresistance to glioblastoma cells

(2017) Ninh B. Doan et al.   ONCOLOGY REPORTS

Radiation therapy for older patients with brain tumors

(2017) Giuseppe Minniti et al.   Radiation Oncology

Short Course Radiotherapy Concomitant with Temozolomide in GBM Patients: A Phase II Study

(2017) Laura Fariselli et al.   TUMORI

Silencing platelet-derived growth factor receptor-β enhances the radiosensitivity of C6 glioma cells in vitro and in vivo

(2017) Ji-Dong Hong et al.   Oncology Letters

Phase I clinical trial of AXL1717 for treatment of relapsed malignant astrocytomas: analysis of dose and response

(2017) Robert Aiken et al.   Oncotarget

A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma

(2017) Isabel Arrillaga-Romany et al.   Oncotarget

Acid ceramidase is a novel drug target for pediatric brain tumors

(2017) Ninh B. Doan et al.   Oncotarget

Acid ceramidase and its inhibitors: a de novo drug target and a new class of drugs for killing glioblastoma cancer stem cells with high efficiency

(2017) Ninh B. Doan et al.   Oncotarget

PDGF Family Expression in Glioblastoma Multiforme: Data Compilation from Ivy Glioblastoma Atlas Project Database

(2017) Isabella Gomes Cantanhede et al.   Scientific Reports

Apoptotic Signaling Pathways in Glioblastoma and Therapeutic Implications

(2017) Silvia Anahi Valdés-Rives et al.   Biomed Research International

Immune Checkpoint in Glioblastoma: Promising and Challenging

(2017) Jing Huang et al.   Frontiers in Pharmacology

HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma

(2017) Nabil Ahmed et al.   JAMA Oncology

Towards Targeting PI3K-Dependent Regulation of Gene Expression in Brain Cancer

(2017) Theo Mantamadiotis   Cancers

Short Course Radiotherapy Concomitant with Temozolomide in GBM Patients: A Phase II Study

(2017) Laura Fariselli et al.   TUMORI JOURNAL

Correction of PTEN mutations in glioblastoma cell lines via AAV-mediated gene editing

(2017) Victoria K. Hill et al.   PLoS One

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

(2016) David N. Louis et al.   ACTA NEUROPATHOLOGICA

Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response?

(2016) A. Lester et al.   Clinical & Translational Oncology

Phase II study of MEDI-575, an anti-platelet-derived growth factor-α antibody, in patients with recurrent glioblastoma

(2016) Surasak Phuphanich et al.   JOURNAL OF NEURO-ONCOLOGY

Advances in immunotherapy for the treatment of glioblastoma

(2016) Amanda Tivnan et al.   JOURNAL OF NEURO-ONCOLOGY

Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma

(2016) Jayashree Kalpathy-Cramer et al.   JOURNAL OF NEURO-ONCOLOGY

Phase I trial of dose-escalating metronomic temozolomide plus bevacizumab and bortezomib for patients with recurrent glioblastoma

(2016) D. Jay McCracken et al.   JOURNAL OF NEURO-ONCOLOGY

Intracranial MR-guided laser-induced thermal therapy: single-center experience with the Visualase thermal therapy system

(2016) Purvee Patel et al.   JOURNAL OF NEUROSURGERY

Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma

(2016) Tracy T. Batchelor et al.   NEURO-ONCOLOGY

Laser interstitial thermal therapy for newly diagnosed and recurrent glioblastoma

(2016) Jonathan G. Thomas et al.   Neurosurgical Focus

Hyperthermic Laser Ablation of Recurrent Glioblastoma Leads to Temporary Disruption of the Peritumoral Blood Brain Barrier

(2016) Eric C. Leuthardt et al.   PLoS One

Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors

(2016) Tadas Rimkus et al.   Cancers

Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis

(2015) Sajeel A. Chowdhary et al.   JOURNAL OF NEURO-ONCOLOGY

Glioblastoma multiforme: Pathogenesis and treatment

(2015) Constantinos Alifieris et al.   PHARMACOLOGY & THERAPEUTICS

International Society of Neuropathology-Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading

(2014) David N. Louis et al.   BRAIN PATHOLOGY

Mouse models of glioblastoma: lessons learned and questions to be answered

(2014) Loury Janbazian et al.   JOURNAL OF NEURO-ONCOLOGY

Vaccine therapies for patients with glioblastoma

(2014) Eli T. Sayegh et al.   JOURNAL OF NEURO-ONCOLOGY

PDGF receptor alpha inhibition induces apoptosis in glioblastoma cancer stem cells refractory to anti-Notch and anti-EGFR treatment

(2014) Carlo Cenciarelli et al.   Molecular Cancer

A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

(2014) Mark R. Gilbert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Platelet-derived growth factor in glioblastoma—driver or biomarker?

(2014) Bengt Westermark   UPSALA JOURNAL OF MEDICAL SCIENCES

IDHMutation in Glioma

(2014) Zorbey Turkalp et al.   JAMA Neurology

The role of laser interstitial thermal therapy in enhancing progression-free survival of difficult-to-access high-grade gliomas: a multicenter study

(2014) Alireza M. Mohammadi et al.   Cancer Medicine

Tumor treating fields: a new frontier in cancer therapy

(2013) Angela M. Davies et al.   Annals of the New York Academy of Sciences

Targeting the PDGF signaling pathway in tumor treatment

(2013) Carl-Henrik Heldin   Cell Communication and Signaling

A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma

(2013) D. A. Reardon et al.   CLINICAL CANCER RESEARCH

IDH1 and IDH2 Mutations in Gliomas

(2013) Adam L. Cohen et al.   Current Neurology and Neuroscience Reports

An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells

(2013) D. Rohle et al.   SCIENCE

The Impact of Extent of Resection and Histological Subtype on the Outcome of Adult Patients with High-grade Gliomas

(2012) S. Yamaguchi et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

PTEN Gene: A Model for Genetic Diseases in Dermatology

(2012) Corrado Romano et al.   TheScientificWorldJOURNAL

Current concepts and management of glioblastoma

(2011) Matthias Preusser et al.   ANNALS OF NEUROLOGY

Essential role of the Hedgehog signaling pathway in human glioma-initiating cells

(2011) Tatsuya Takezaki et al.   CANCER SCIENCE

Pathway inhibition: emerging molecular targets for treating glioblastoma

(2011) W. Wick et al.   NEURO-ONCOLOGY

Regulation of glioblastoma stem cells by retinoic acid: role for Notch pathway inhibition

(2011) M Ying et al.   ONCOGENE

Notch signaling in glioblastoma: a developmental drug target?

(2010) Maria Maddalena Lino et al.   BMC Medicine

PI3Kinase signaling in glioblastoma

(2010) M. M. Lino et al.   JOURNAL OF NEURO-ONCOLOGY

Inhibition of Notch Signaling in Glioblastoma Targets Cancer Stem Cells via an Endothelial Cell Intermediate

(2010) Koos E. Hovinga et al.   STEM CELLS

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

FDA Drug Approval Summary: Bevacizumab (Avastin(R)) as Treatment of Recurrent Glioblastoma Multiforme

(2009) M. H. Cohen et al.   ONCOLOGIST

Notch Pathway Blockade Depletes CD133-Positive Glioblastoma Cells and Inhibits Growth of Tumor Neurospheres and Xenografts

(2009) Xing Fan et al.   STEM CELLS

‘Recurrent’ glioblastoma multiforme, when should we reoperate?

(2008) Giuseppe M. V. Barbagallo et al.   BRITISH JOURNAL OF NEUROSURGERY

Surgical management of newly diagnosed glioblastoma in adults: role of cytoreductive surgery

(2008) Timothy C. Ryken et al.   JOURNAL OF NEURO-ONCOLOGY

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE